Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Breast Neoplasms 2043Neoplasms 1458Carcinoma, Non-Small-Cell Lung 1360Prostatic Neoplasms 1104Multiple Myeloma 870Leukemia, Myeloid, Acute 767Colorectal Neoplasms 710Neoplasm Metastasis 702Lung Neoplasms 696Melanoma 683Lymphoma 665Leukemia 595Lymphoma, Non-Hodgkin 592Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 530Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 483Recurrence 474Myelodysplastic Syndromes 424Lymphoma, Follicular 418Carcinoma, Renal Cell 410Head and Neck Neoplasms 407Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 374Hodgkin Disease 354Carcinoma, Hepatocellular 332Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Paclitaxel 2Carboplatin 2Albumin-Bound Paclitaxel 2osimertinib 1aumolertinib 1Taxes 1Pemetrexed 1Gemcitabine 1Clinical Trials, Phase I as Topic 1Cisplatin 1Cetuximab 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × NSCLC × Clear all
NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Bridge Biotherapeutics, Inc.

Phase 1/2 Terminated
45 enrolled 19 charts
Thoracic

NSCLC

NCT04402008 2024-06-25

Study of Poziotinib in Japanese Patients With NSCLC

Spectrum Pharmaceuticals, Inc

Phase 1/2 Terminated
42 enrolled 16 charts
Thoracic

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT00874848 2016-11-29

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

HiberCell, Inc.

Phase 2 Completed
90 enrolled 20 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡